StudyType	PubMedID	Author	Title	Journal	PublishDate	Chromosome	Disease	Technology	Species	CaseID	Platform	CNA	Connection	Gene	Affiliation	Abstract	GenomeAssembly	GEO	dbGaP	ENA	IsCancer	FusionGene
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	2	Multiple myeloma	SNP Array	Homo sapiens	MM_06358	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	1,3	Multiple myeloma	SNP Array	Homo sapiens	MM_07545	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	16,17	Multiple myeloma	SNP Array	Homo sapiens	MM_08186	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	3	Multiple myeloma	SNP Array	Homo sapiens	MM_09402	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	10,12	Multiple myeloma	SNP Array	Homo sapiens	MM_10217	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	8,18	Multiple myeloma	SNP Array	Homo sapiens	MM_10353	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	1	Multiple myeloma	SNP Array	Homo sapiens	MM_10389	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	16	Multiple myeloma	SNP Array	Homo sapiens	MM_11762	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA
Research	21628407	Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients	Blood	2011 Jul	16	Multiple myeloma	SNP Array	Homo sapiens	MM_06415	Affymetrix SNP6 Array				Inserm U892, Universite de Nantes, Nantes, France	Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.	GRCh37/hg19	GSE27560			Yes	NA